463 related articles for article (PubMed ID: 30486605)
1. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
2. Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand.
Kongsiang A; Tangvoraphonkchai V; Jirapornkul C; Promthet S; Kamsa-Ard S; Suwanrungruang K
Asian Pac J Cancer Prev; 2014; 15(23):10505-8. PubMed ID: 25556500
[TBL] [Abstract][Full Text] [Related]
3. Association between common risk factors and molecular subtypes in breast cancer patients.
Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738
[TBL] [Abstract][Full Text] [Related]
4. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.
Effi AB; Aman NA; Koui BS; Koffi KD; Traore ZC; Kouyate M
Asian Pac J Cancer Prev; 2016; 17(4):1973-8. PubMed ID: 27221883
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen and progesterone receptors in human ductal invasive breast carcinoma not otherwise specified: is there any difference between premenopausal and postmenopausal women?
Petricević J; Petković M; Jonjić N
Acta Clin Croat; 2011 Jun; 50(2):169-75. PubMed ID: 22263379
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
11. HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy.
Jia H; Jia W; Yang Y; Li S; Feng H; Liu J; Rao N; Jin L; Wu J; Gu R; Zhu L; Chen K; Deng H; Zeng Y; Liu Q; Song E; Su F
World J Surg Oncol; 2014 Sep; 12():289. PubMed ID: 25241216
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
14. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Survival Defined by Biological Receptor and Menopausal Status in Vietnamese Women.
Vu Hong T; Nguyen Ba D; Skoog L; Ta Thanh V; Tani E
Cancer Control; 2019; 26(1):1073274819865279. PubMed ID: 31343899
[TBL] [Abstract][Full Text] [Related]
16. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
17. Impact of triple negative phenotype on prognosis and early onset of breast cancer in Iranian females.
Salami S; Ramezani F; Aghazadeh T; Afshin-Alavi H; Ilkhanizadeh B; Maleki D
Asian Pac J Cancer Prev; 2011; 12(3):719-24. PubMed ID: 21627371
[TBL] [Abstract][Full Text] [Related]
18. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the effect of menopausal status and molecular subtype on survivals among breast cancer patients].
Zuo TT; Zeng HM; Zheng RS; Yang L; Li HC; Liu S; Xia CF; Chen WQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 May; 51(5):409-414. PubMed ID: 28464591
[No Abstract] [Full Text] [Related]
20. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
Dartois L; Fagherazzi G; Baglietto L; Boutron-Ruault MC; Delaloge S; Mesrine S; Clavel-Chapelon F
Int J Cancer; 2016 May; 138(10):2415-27. PubMed ID: 26756677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]